Sugi Predict

Sugi Predict / Compounds / SCHEMBL5757045

SCHEMBL5757045

SCHEMBL5757045

CCCCCSc1nc2ccc(S(=O)(=O)N(Cc3ccccc3)[C@H](CC(C)C)C(=O)NO)cc2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 4/20 0.43
▸ MMP2 P08253 3/20 0.43
▸ MMP9 P14780 3/20 0.43
▸ MMP8 P22894 2/20 0.43
▸ MMP1 P03956 2/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ MAPT P10636 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PPARG P37231 2/20 0.40
▸ PPARA Q07869 2/20 0.40
▸ ALOX5 P09917 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ MMP3 P08254 3/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5754680 0.92 MAPT (0.42) MAPTTP53PPARGPPARAALOX5
SCHEMBL7221099 0.92 PPARG (0.42) MMP13MMP2MMP9MMP8MAPT
SCHEMBL5759636 0.91 TP53 (0.43) MAPTTP53PPARGPPARAALOX5
SCHEMBL5757291 0.90 MMP3 (0.46) MMP13MMP2MMP9MMP1MAPT
SCHEMBL5757049 0.89 MMP2 (0.52) MMP13MMP2MMP9MMP8MMP1
SCHEMBL5754582 0.89 MMP2 (0.51) MMP13MMP2MMP9MMP8MMP1
SCHEMBL5759862 0.89 MMP2 (0.51) MMP13MMP2MMP9MMP8MMP1
SCHEMBL5754601 0.89 MMP2 (0.51) MMP13MMP2MMP9MMP8MMP1
SCHEMBL5756413 0.87 MMP2 (0.53) MMP13MMP2MMP9MMP8MMP1
SCHEMBL5755663 0.86 PPARG (0.43) MAPTTP53PPARGPPARAALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 — — EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 — — US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 — — EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 — — US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 — — EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP13 21/4885MMP2 8/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.